Nagarjun Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.80 Cr
- Company Age 30 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 21.40 Cr
- Satisfied Charges ₹ 17.43 Cr
- Revenue Growth 19.13%
- Profit Growth 0.30%
- Ebitda 18.85%
- Net Worth 7.83%
- Total Assets 5.97%
About Nagarjun Pharmaceuticals
Nagarjun Pharmaceuticals Pvt Ltd (NPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 19 January 1995 and has a history of 30 years and one month. Its registered office is in Gandhi Nagar, Gujarat, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.80 Cr.
The company currently has active open charges totaling ₹21.40 Cr. The company has closed loans amounting to ₹17.43 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vaidehiben Joshi, Atrey Joshi, and Satishkumar Sharma serve as directors at the Company.
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231GJ1995PTC024260
- Company No.
024260
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Jan 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
What products or services does Nagarjun Pharmaceuticals Pvt Ltd offer?
Nagarjun Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Split Air Conditioners, Blue Star Split Air Conditioners, Ayurvedic,Herbal Products & Medicine, Ayurvedic Pain Relief Oil, Hair Oil, Herbal Hair Oil, Air Conditioner, Inverter Air Conditioners, Cosmetics, Hair & Beauty Products, Body Cream.
Who are the key members and board of directors at Nagarjun Pharmaceuticals?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Atrey Joshi ![]() | Director | 05-Mar-2012 | Current |
Vaidehiben Joshi ![]() | Director | 19-Jan-1995 | Current |
Satishkumar Sharma ![]() | Director | 19-Jan-1995 | Current |
Financial Performance of Nagarjun Pharmaceuticals.
Nagarjun Pharmaceuticals Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 19.13% increase. The company also saw a slight improvement in profitability, with a 0.3% increase in profit. The company's net worth moved up by a moderate rise of 7.83%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Nagarjun Pharmaceuticals?
Unlock access to Nagarjun Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Charges (Loans)
₹21.40 Cr
₹17.43 Cr
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 17.63 Cr
- Others : 3.60 Cr
- State Bank Of Inidia : 0.17 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
16 Jul 2024 | Axis Bank Limited | ₹4.67 M | Open |
11 Jan 2024 | Axis Bank Limited | ₹1.65 Cr | Open |
11 Jul 2022 | Axis Bank Limited | ₹1.61 Cr | Open |
20 Jun 2022 | Axis Bank Limited | ₹9.50 Cr | Open |
05 Mar 2022 | Axis Bank Limited | ₹4.40 Cr | Open |
How Many Employees Work at Nagarjun Pharmaceuticals?
Nagarjun Pharmaceuticals has a workforce of 79 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Nagarjun Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nagarjun Pharmaceuticals's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.